The Effect of Vitamin B3 on Substrate Metabolism, Insulin Sensitivity, and Body Composition in Obese Men

The Effect of Nicotinamide Ribose (NR) on Substrate Metabolism, Insulin Sensitivity, and Body Composition in Obese Men - a Randomized, Placebo Controlled Clinical Trial

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02303483

Enrollment

Registered

2014-12-01

Start date

2016-01-04

Completion date

2017-04-04

Last updated

2017-07-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obese

Brief summary

In animals, treatment with vitamin B3 improved insulin sensitivity and substrate metabolism. It is currently not know if vitamin B3 has the same positive effects in humans. In the current study the effect of a 3 month treatment with vitamin B3 on insulin sensitivity and substrate metabolism in obese men will be investigated.

Interventions

DIETARY_SUPPLEMENTNicotinamide riboside (NIAGEN TM, ChromaDex, CA, USA )

DIETARY_SUPPLEMENTPlacebo

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

MALE

Age

40 Years to 70 Years

Healthy volunteers

Yes

Inclusion criteria

* written signed consent * male * BMI\>30 kg/(m2) * age: 40-70 * no medication * non-smoker

Exclusion criteria

* endocrine disease * other severe disease * high daily activity level (\>30 min / day)

Design outcomes

Primary

Measure	Time frame	Description
Insulin sensitivity	Change from baseline in insulin sensitivity at 3 months	determined by a hyperinsulineamic clamp

Secondary

Measure	Time frame	Description
body composition	Change from baseline in body composition at 3 months	measured by DEXA scan
Activation of satellite cells	Change from baseline in activation of satellite cells at 3 months	measured by immunohistochemestry
lipid accumulation in liver and skeletal muscle tissue	Change from baseline in liver and muscle lipid content at 3 months	determined by MR-spectroscopy
glucose turnover	Change from baseline in glucose turnover at 3 months	determined by glucose tracer techniques
Substrate metabolism	Change from baseline in substrate metabolism at 3 months	measured by indirect calorimetry
Palmitate turnover	Change from baseline in palmitate turnover at 3 months	determined by palmitate tracer techniques
Gut microbiota	Change from baseline in composition of gut microbiota at 3 months	Intestinal bacteria composition by whole genome sequencing
Incretin hormone secretion	Change from baseline in incretion hormone secretion at 3 months	Determined by measurement of incretin homones during an oral glucose tolerance test (OGTT)
insulin signalling in skeletal muscle and adipose tissue biopsies	Change from baseline in insulin signaling at 3 months	western blotting

Countries

Denmark

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 5, 2026